These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 24581432)

  • 61. Omalizumab for the treatment of severe persistent allergic asthma in children aged 6-11 years.
    Walker S; Burch J; McKenna C; Wright K; Griffin S; Woolacott N
    Health Technol Assess; 2011 May; 15 Suppl 1():13-21. PubMed ID: 21609649
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study.
    Hanania NA; Wenzel S; Rosén K; Hsieh HJ; Mosesova S; Choy DF; Lal P; Arron JR; Harris JM; Busse W
    Am J Respir Crit Care Med; 2013 Apr; 187(8):804-11. PubMed ID: 23471469
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Lack of pretreatment cost-effectiveness and side effects of omalizumab versus prednisone/montelukast on tolerability of immunotherapy.
    Rosenberg JL
    J Allergy Clin Immunol; 2011 Feb; 127(2):548; author reply 548-9. PubMed ID: 21281877
    [No Abstract]   [Full Text] [Related]  

  • 64. The use of biological agents for the treatment of fungal asthma and allergic bronchopulmonary aspergillosis.
    Moss RB
    Ann N Y Acad Sci; 2012 Dec; 1272():49-57. PubMed ID: 23231714
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Immunotherapy in miscellaneous medical disorders Graves ophthalmopathy, asthma, and regional painful syndrome.
    Gonzales M; Fratianni C; Mamillapali C; Khardori R
    Med Clin North Am; 2012 May; 96(3):635-54, xi. PubMed ID: 22703859
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Poorly controlled asthma: diagnosis and therapeutics in children and adolescents].
    Neffen H; Vidaurreta S; Balanzat A; De Gennaro MS; Giubergia V; Maspero JF; Saranz RJ; Teper AM
    Medicina (B Aires); 2012; 72(5):403-13. PubMed ID: 23089117
    [TBL] [Abstract][Full Text] [Related]  

  • 67. High eosinophil count: a potential biomarker for assessing successful omalizumab treatment effects.
    Busse W; Spector S; Rosén K; Wang Y; Alpan O
    J Allergy Clin Immunol; 2013 Aug; 132(2):485-6.e11. PubMed ID: 23591271
    [No Abstract]   [Full Text] [Related]  

  • 68. Allergen immunotherapy: a history of the first 100 years.
    Fitzhugh DJ; Lockey RF
    Curr Opin Allergy Clin Immunol; 2011 Dec; 11(6):554-9. PubMed ID: 21971334
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Effectiveness of omalizumab in non-allergic severe asthma.
    Domingo C; Pomares X; Angril N; Rudi N; Amengual MJ; Mirapeix RM
    J Biol Regul Homeost Agents; 2013; 27(1):45-53. PubMed ID: 23489686
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Oral corticosteroid sparing with omalizumab in severe allergic (IgE-mediated) asthma patients.
    Siergiejko Z; Świebocka E; Smith N; Peckitt C; Leo J; Peachey G; Maykut R
    Curr Med Res Opin; 2011 Nov; 27(11):2223-8. PubMed ID: 21933100
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [Omalizumab and allergen immunotherapy: A clinical report and review of the literature].
    Carrier C; Demoly P; Caimmi D
    Rev Mal Respir; 2019 Feb; 36(2):191-196. PubMed ID: 30396780
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Persistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthma.
    Bousquet J; Siergiejko Z; Swiebocka E; Humbert M; Rabe KF; Smith N; Leo J; Peckitt C; Maykut R; Peachey G
    Allergy; 2011 May; 66(5):671-8. PubMed ID: 21255035
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [Anti-IgE therapy in persistent allergic asthma].
    Skiepko R; Zietkowski Z; Tomasiak-Łozowska MM; Bodzenta-Łukaszyk A
    Przegl Lek; 2009; 66(3):141-4. PubMed ID: 19689039
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [The value of omazulimab in the treatment of severe asthma].
    Miao WW; Wang FF; Li HY
    Zhonghua Jie He He Hu Xi Za Zhi; 2012 Mar; 35(3):198-200. PubMed ID: 22781153
    [No Abstract]   [Full Text] [Related]  

  • 75. The anti-IgE antibody omalizumab as a probe to investigate the role of IgE in pathology.
    Mauro M; Incorvaia C; Formigoni C; Elia R; Russello M; Pellegrino D
    Panminerva Med; 2012 Dec; 54(4):305-12. PubMed ID: 23123583
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Refractory asthma - beyond step 5, the role of new and emerging adjuvant therapies.
    Kane B; Fowler SJ; Niven R
    Chron Respir Dis; 2015 Feb; 12(1):69-77. PubMed ID: 25492977
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Eosinophil count and efficacy of omalizumab treatment.
    Panasoff J
    J Allergy Clin Immunol; 2014 Apr; 133(4):1231. PubMed ID: 24679472
    [No Abstract]   [Full Text] [Related]  

  • 78. Options of immunotherapeutic treatments for children with asthma.
    Porcaro F; Cutrera R; Pajno GB
    Expert Rev Respir Med; 2019 Oct; 13(10):937-949. PubMed ID: 31414917
    [No Abstract]   [Full Text] [Related]  

  • 79. Omalizumab and allergen immunotherapy in a patient with asthma and inhaled corticosteroid-induced adrenal suppression.
    Forbush JT; Banks TA
    Ann Allergy Asthma Immunol; 2016 Sep; 117(3):335-7. PubMed ID: 27613470
    [No Abstract]   [Full Text] [Related]  

  • 80. Omalizumab treatment in 2 cases of refractory heat urticaria.
    Carballada F; Nuñez R; Martin-Lazaro J; Juárez Y; Castiñeira I; Carballada F; Nuñez R; Martin-Lazaro J; Juárez Y; Castiñeira I; Fernández L; Boquete M
    J Investig Allergol Clin Immunol; 2013; 23(7):519-21. PubMed ID: 24654322
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.